Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Scott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Naiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2007
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford, Christopher R Garrett, Neal J Meropol, et al.
The New England Journal of Medicine
|
November 20, 2014
Genetic basis for clinical response to CTLA-4 blockade in melanoma
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, et al.
Nature
|
September 3, 2004
Transcriptional regulatory code of a eukaryotic genome
Christopher T Harbison, D Benjamin Gordon, Tong Ihn Lee, et al.
Science (New York, N.Y.)
|
October 26, 2002
Transcriptional regulatory networks in Saccharomyces cerevisiae
Tong Ihn Lee, Nicola J Rinaldi, François Robert, et al.
JAMA Oncology
|
July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
The Lancet. Oncology
|
June 9, 2016
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J Antonia, José A López-Martin, Johanna Bendell, et al.
The New England Journal of Medicine
|
June 2, 2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer, Karen L Reckamp, Paul Baas, et al.
The New England Journal of Medicine
|
September 29, 2015
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Hossein Borghaei, Luis Paz-Ares, Leora Horn, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Scott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Naiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2007
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford, Christopher R Garrett, Neal J Meropol, et al.
The New England Journal of Medicine
|
November 20, 2014
Genetic basis for clinical response to CTLA-4 blockade in melanoma
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, et al.
Nature
|
September 3, 2004
Transcriptional regulatory code of a eukaryotic genome
Christopher T Harbison, D Benjamin Gordon, Tong Ihn Lee, et al.
Science (New York, N.Y.)
|
October 26, 2002
Transcriptional regulatory networks in Saccharomyces cerevisiae
Tong Ihn Lee, Nicola J Rinaldi, François Robert, et al.
JAMA Oncology
|
July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
The Lancet. Oncology
|
June 9, 2016
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J Antonia, José A López-Martin, Johanna Bendell, et al.
The New England Journal of Medicine
|
June 2, 2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer, Karen L Reckamp, Paul Baas, et al.
The New England Journal of Medicine
|
September 29, 2015
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Hossein Borghaei, Luis Paz-Ares, Leora Horn, et al.
Page
of 3